S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer

The development of resistance to EGFR Tyrosine kinase inhibitors (TKIs) in NSCLC with activating EGFR mutations is a critical limitation of this therapy. In addition to genetic alterations such as EGFR secondary mutation causing EGFR-TKI resistance, compensatory activation of signaling pathways with...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Hua, Wang, Gao-Chan, Li, Xiang, Ge, Xin, Wang, Meng, Shi, Zhu-Mei, Bhardwaj, Vikas, Wang, Zi-Xuan, Zinner, Ralph G., Peiper, Stephen C., Aplin, Andrew E., Jiang, Bing-Hua, He, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718330/
https://www.ncbi.nlm.nih.gov/pubmed/33037411
http://dx.doi.org/10.1038/s41388-020-01497-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718330/
https://www.ncbi.nlm.nih.gov/pubmed/33037411
http://dx.doi.org/10.1038/s41388-020-01497-4

Ejemplares similares